2021
DOI: 10.1016/bs.apcsb.2020.08.003
|View full text |Cite
|
Sign up to set email alerts
|

Serum albumin: clinical significance of drug binding and development as drug delivery vehicle

Help me understand this report

Search citation statements

Order By: Relevance

Paper Sections

Select...
3
1
1

Citation Types

0
26
0

Year Published

2021
2021
2024
2024

Publication Types

Select...
10

Relationship

0
10

Authors

Journals

citations
Cited by 61 publications
(26 citation statements)
references
References 81 publications
0
26
0
Order By: Relevance
“…The mechanism of low serum albumin leading to poor tumor prognosis is complex. For example, low serum albumin level could impair the body’s natural defense mechanisms [ 25 ], reduce the efficiency of treatment options [ 26 ], as well as delayed recovery and increased mortality [ 27 ]. Various blood examination-based nutritional parameters have been implicated in tumor prognosis (prognostic nutritional index [ 28 ], albumin-globulin ratio [ 29 ] and c-reactive protein to albumin ratio [ 30 ]).…”
Section: Discussionmentioning
confidence: 99%
“…The mechanism of low serum albumin leading to poor tumor prognosis is complex. For example, low serum albumin level could impair the body’s natural defense mechanisms [ 25 ], reduce the efficiency of treatment options [ 26 ], as well as delayed recovery and increased mortality [ 27 ]. Various blood examination-based nutritional parameters have been implicated in tumor prognosis (prognostic nutritional index [ 28 ], albumin-globulin ratio [ 29 ] and c-reactive protein to albumin ratio [ 30 ]).…”
Section: Discussionmentioning
confidence: 99%
“…A better knowledge of mycolactone interaction with serum carriers is thus essential for the therapeutic use of mycolactone. Many studies report efforts to develop drug delivery systems using albumin or HDLs as a drug carriers ( Wasan et al, 2008 ; Larsen et al, 2016 ; Hoogenboezem and Duvall, 2018 ; Tayyab et al, 2021 ). Accumulation of albumin in solid tumors as well as overexpression of SR-B1 in most malignancies warrant developing carrier-based drug delivery systems for tumor targeting ( Larsen et al, 2016 ; Raut et al, 2018 ).…”
Section: Discussionmentioning
confidence: 99%
“…Whereas a low binding affinity suggests immediate availability of the administered compound, a high binding affinity infers that HSA may function as a reservoir maintaining homogeneous distribution to the tissues thereby increasing biological lifetimes [45]. Considering its role on overall drug pharmacokinetics [46], HSA may limit and/or control toxicity while modulating metabolic inactivation and elimination through excretory pathways. A secondary yet equally relevant objective underlying initial assessment of HSA binding properties is to identify predominant molecular species in the compound mixture and determine an average molecular weight.…”
Section: Experimental Strategymentioning
confidence: 99%